BMY stock: buy or sell?
February 21st, 2020
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide.
Should I buy BMY stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to define your own trading plan that matches with your character as inversor. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, Bristol-Myers Squibb stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Bristol-Myers Squibb stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't find any rating for BMY stock for the last 30 days.
BMY stock analysis
Bristol-Myers Squibb shares stepped up 0.71% to $65.63 today.
Shares of Bristol-Myers Squibb closed today at $65.63 and stepped up a tiny 0.71%. Since SMA100d and SMA200d crossed up on October, BMY price climbed $11.59 per share (21.45%).
Bristol-Myers Squibb shares depreciated -1.13% this week, ending at $65.63.
Price pattern shows an uptrend with two rising tops and bottoms, and now trading upwards to the $68.34 resistance. Since late October 2019 when SMA20w and SMA40w crossed up, BMY price gained $12.97 per share (24.63%). Since price and SMA40w lines crossed up late August 2019, BMY climbed $19.76 (43.08%).
BMY stock price history
BMY stock historical price chart
BMY stock reached 52-week highs on January/22 at $68.34, and all-time highs 2016-07-15 with a price of 69.7.
BMY stock price targetPredicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. You should not follow the analysts' BMY stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we have not found any price target for Bristol-Myers Squibb stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareSince April, when Bristol-Myers Squibb presented its last earnings report, it . Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual revenues report draw a remarkable gain of 8.59% to $22,561.00 M USD. When comparing 2018 vs 2017, likewise, profit margin (that is, the net income divided by revenues) skyrocketed a 16.96% to 21.81%. Bristol-Myers Squibb fiscal year ends in December, and to evaluate its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Bristol-Myers Squibb TTM sales up to March 2019 were $23,288.00 and earnings $5,144.00 M dollars. When comparing this TTM figures with the last reported annuality, we can review Bristol-Myers Squibb business evolution since December 2018: Annual turnover up to March, compared to lastest yearly report, appreciated a beatiful 3.22%. Regarding profit margin, Bristol-Myers Squibb remained steady 0.28% to 21.81%
|2013||$16,390 M||-||$2,560 M15.6%||-|
|2014||$15,879 M||-3.12%||$2,004 M12.6%||-21.72%|
|2015||$16,560 M||4.29%||$1,565 M9.5%||-21.91%|
|2016||$19,427 M||17.31%||$4,457 M22.9%||184.79%|
|2017||$20,776 M||6.94%||$1,007 M4.8%||-77.41%|
|2018||$22,561 M||8.59%||$4,920 M21.8%||388.58%|
|TTM||$23,288 M||3.22%||$5,144 M22.1%||4.55%|
Quarterly financial resultsBristol-Myers Squibb posted $5,920.00 million in revenues for 2019-Q1, a -0.89% decline compared to previous quarter. Reported quarter income marked $1,710.00 million with a profit margin of 28.89%. Profit margin soared a 9.46% compared to previous quarter when profit margin was 19.42%. When comparing sales to same quarter last year, Bristol-Myers Squibb sales marked an amazing growth and rocketed a 14.00%.
|2017-Q2||$5,140 M||-||$916 M17.8%||-|
|2017-Q3||$5,250 M||2.14%||$845 M16.1%||-7.75%|
|2017-Q4||$5,449 M||3.79%||$-2,328 M-42.7%||-375.50%|
|2018-Q1||$5,193 M||-4.70%||$1,486 M28.6%||-163.83%|
|2018-Q2||$5,704 M||9.84%||$373 M6.5%||-74.90%|
|2018-Q3||$5,691 M||-0.23%||$1,901 M33.4%||409.65%|
|2018-Q4||$5,973 M||4.96%||$1,160 M19.4%||-38.98%|
|2019-Q1||$5,920 M||-0.89%||$1,710 M28.9%||47.41%|
Bristol-Myers Squibb ownershipWhen you are planning to buy shares of a company, it's always worth to overview its ownership structure.
Bristol-Myers Squibb shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.10% of all shares.
In case of Bristol-Myers Squibb stock, 62.07% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for BMY stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Bristol-Myers Squibb:
|Market cap||$107.0 B|
|Total shares||1,630.0 M|
|Float shares||1,630.0 M|
|- Institutional holdings (%)||62.1%|
|- Insider holdings (%)||0.1%|
|Shares in short selling||0.0%|
|Friday, February 21st, 2020|
|Day range||$64.80 - $65.87|
|Average true range||$1.20|
|50d mov avg||$64.67|
|100d mov avg||$59.77|
|200d mov avg||$52.88|
Bristol-Myers Squibb performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. In the following table, we compare Bristol-Myers Squibb to :
Bristol-Myers Squibb competitorsUnfortunately, we could not find any public company that could be defined as Bristol-Myers Squibb competitor. This doesn't mean Bristol-Myers Squibb does not have any competitor in the market, it's just we could not detected it.
Latest BMY stock news
- InvestorPlaceBristol-Myers Squibb Earnings: BMY Stock Bounces on Strong Q2, GuidanceJuly 25, 2019
- InvestorPlaceWhy Bristol-Myers Squibb Stock Is Stumbling Ahead of EarningsJuly 23, 2019
- Seeking AlphaBristol-Myers Squibb Is CheapJuly 3, 2019
- Seeking AlphaBristol-Myers Squibb And Celgene - On The Path To A Valuable CombinationJune 20, 2019
- InvestorPlaceBristol-Myers Squibb Earnings: BMY Stock Pops on Q1 BeatApril 25, 2019